Description
The global clinical biomarker testing market size was recorded around USD 10.89 billion in 2020 and reach USD 24.66 billion by 2027, registering a CAGR of 14.6% during the forecast period, 2021-2027. Clinical biomarker testing is the procedure that identifies the molecular signs of health in a human body, helping healthcare professionals to explain and strengthen the quality of patient care provided. Biomarker testing is also known as genetic or molecular testing, which will continue to be among the most sought-after techniques among researchers. This is expected to remain the key factor driving the growth of the clinical bio market testing market. In line with the exponentially rising prevalence of cancers worldwide, oncology will especially remain the top application area as clinical bio market testing finds wide application in tumor testing/tumor genetic testing/tumor profiling.
Major Factors Likely to be Impacting Clinical Biomarker Testing Industry over Forecast Period
The advancements in molecular techniques, rising uptake of biomarker tests by healthcare professionals, and boosting research and funding activities for clinical biomarker testing will raise the demand for clinical biomarker testing, offering new growth avenues to the global market for clinical biomarker testing. Factors such as increasing involvement of patients in personal healthcare or fitness-conscious and rising prevalence of genetic and chronic diseases such as diabetes, cancers, cardiovascular disorders, others are anticipated to drive the global growth for clinical biomarker testing market.
Mounting demand for clinical biomarkers in various technologies such as ultra-high-throughput sequencing and next-generation sequencing technologies has positively impacted the sales of clinical biomarker testing in the healthcare and pharmaceutical sector across the globe significantly. However, the poor reimbursement scenario, lack of testing centers, and stringent and uncertain regulatory framework may restrain the growth of clinical biomarker testing in the global market over the forecast period.
Get Full PDF Sample Copy of Report: https://www.marketstatsville.com/request-sample/clinical-biomarker-testing-market
Impact of COVID-19 on Clinical Biomarker Testing Market
The outbreak of COVID-19 increased the demand for clinical biomarker testing as there is an excruciating need to screen for tests for a large number of patients across several sectors, primarily the health and pharmaceutical sector. As the coronavirus crisis continues to take over the world, impacting many businesses worldwide, there has been a significant surge in demand for clinical biomarker testing that has been seen across the globe, positively impacting the clinical biomarker testing market value in 2020 and subsequent years.
Scope of the Report
The report outlines the global clinical biomarker testing market study based on technology, application, and end-user.
The clinical biomarker testing market has been segmented based on technology –
- Ultra-high Throughput Sequencing
- Next-generation Sequencing
- Others
The clinical biomarker testing market has been segmented based on application –
- Cancer
- Cardiovascular
- Nervous system
- Infectious diseases
- Others
The clinical biomarker testing market has been segmented based on the end user –
- Pharma & Biotech Companies
- Diagnostic tool companies
- Clinical Laboratories
- Healthcare IT
Clinical Biomarker Testing Market: Regional Outlook
Based on the region, the global clinical biomarker testing market has been segmented into five geographical regions, namely, North America, Asia Pacific, Europe, South America, and the Middle East, and Africa. In 2020, North America held the largest share in the clinical biomarker testing market, followed by the Asia Pacific and Europe due to favorable government initiatives and the increasing disease burden in the region.
Moreover, Asia Pacific is expected to project the highest CAGR globally over the forecast period due to increasing R&D investment and vital biomarker companies in the region.
Make an Enquire before Purchase @: https://www.marketstatsville.com/buy-now/clinical-biomarker-testing-market?opt=2950
Key Global Clinical Biomarker Testing Market Competitors Includes –
The clinical biomarker testing market is highly fragmented, with the presence of a large number of small players across the globe. The vital clinical biomarker testing market manufacturers operating in the global market are –
- Novartis
- GlaxoSmithKline
- F. Hoffmann-La Roche AG
- Pfizer Inc.
- GE Healthcare
- Medtronics plc
- LECO Corporation
- Metabolon Inc.
- Biocrates LifeSciences AG
- Danaher Corporation
- Agilent Technologies
- Thermo Fisher Scientific Co.
- Shimadzu Corporation
- Bio-Rad Laboratories
- Quest Diagnostics.
The clinical biomarker testing market report thoroughly analyzes macro-economic factors and every segment’s market attractiveness. The report will include an in-depth qualitative and quantitative assessment of the segmental/regional outlook with the market players’ presence in the respective segment and region/country. The information concluded in the report includes the inputs.
Request for Complete TOC and Figures & Graphs @ https://www.marketstatsville.com/table-of-content/clinical-biomarker-testing-market
Clinical Biomarker Testing Market Report Covers Comprehensive Analysis On:
- Market Segmentation & Regional Analysis
- Market Size of 10 years
- Pricing Analysis
- Supply & Demand Analysis
- Product Life Cycle Analysis
- Porter’s Five Forces & Value Chain Analysis
- Developed & Emerging Economies Analysis
- PEST Analysis
- Market and Forecast Factor Analysis
- Market Opportunities, Risks, & Trends
- Conclusion & Recommendation
- Regulatory Landscape
- Patent Analysis
- Competition Landscape
- 15+ Company Profiles
Clinical Biomarker Testing Market Regional Analysis Includes:
- North America (US, Canada, Mexico)
- South America (Brazil, Argentina, Colombia, Peru, Rest of Latin America)
- Europe (Germany, Italy, France, UK, Spain, Poland, Russia, Slovenia, Slovakia, Hungary, Czech Republic, Belgium, the Netherlands, Norway, Sweden, Denmark, Rest of Europe)
- Asia Pacific (China, Japan, India, South Korea, Indonesia, Malaysia, Thailand, Vietnam, Myanmar, Cambodia, the Philippines, Singapore, Australia & New Zealand, Rest of Asia Pacific)
- The Middle East & Africa (Saudi Arabia, UAE, South Africa, Northern Africa, Rest of MEA
Request For Report Description @ https://www.marketstatsville.com/clinical-biomarker-testing-market
Clinical Biomarker Testing Market: Target Audience
- Clinical biomarker testing manufacturers and suppliers
- Investors and trade experts
- Large, medium, and small-sized enterprises
- Hospitals and clinics
- Trade publications and magazines
- Government authorities, associations, and organizations
About US:
Market Statsville Group (MSG) partners with companies and society to confront their essential risks and challenges to capture the enormous opportunities for them. MSG initiated its work in 2017, and since then, the brand is moving to become a pioneer in business advisory and market research services.
We the leading market research and strategy builder with the depth and breadth of solutions that perfectly suit your every need. MSG provides solutions in a wide range of industry verticals in market sizing, analysis, and incisive business insights. MSG experienced research analysts are proficient at digging deep and providing various customizable data that help you make decisions with clarity, confidence, and impact.
Contact US: Market Statsville Group
Eric Martin
416, East standsberry street,
Perkins, Oklahoma 74059, US
USA: +1-580-205-2707 | India: +91-702-496-8807
Email: mailto:sales@marketstatsville.com
MSG Blog https://marketstatsvilleblogs.com/
Web: https://marketstatsville.com/
LinkedIn | Facebook | Twitter